Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test

Qing Sun, Jonathan Li, Hui Ren, Larry Pastor, Yulia Loginova, Roberta Madej, Kristopher Taylor, Joseph K. Wong, Zhao Zhang, Aiguo Zhang, Chuanyi M. Lu, Michael Y. ShamedRxiv 2020 · DOI

Abstract

Sensitive and high-throughput molecular detection assays are essential for managing the COVID-19 pandemic. While nasopharyngeal swabs (NPS) are the standard specimen, they present challenges including patient discomfort and risks to healthcare workers. This study validates the QuantiVirus™ SARS-CoV-2 multiplex test for use with saliva specimens. The assay demonstrates a limit of detection (LOD) of 100–200 copies/mL and shows high clinical performance comparable to NPS-based testing. Furthermore, the study confirms the feasibility of saliva sample pooling (up to 6 samples), providing a scalable solution for population-wide screening.

Introduction

Since the emergence of SARS-CoV-2, molecular detection via real-time reverse transcription-polymerase chain reaction (RT-PCR) has been the primary diagnostic tool. Traditionally, these assays rely on nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens. However, the collection of these samples is invasive, often causing patients to cough or sneeze, which increases the risk of viral transmission to healthcare providers. This risk necessitates the heavy use of personal protective equipment (PPE) and specialized training for collection personnel.

Saliva has emerged as a promising alternative specimen. It can be self-collected, reducing the burden on healthcare infrastructure and improving patient compliance. This paper evaluates the performance of the QuantiVirus™ SARS-CoV-2 multiplex test, focusing on its sensitivity, clinical agreement with NPS, and its application in high-throughput pooled testing environments.

Methodology

The QuantiVirus™ Multiplex Assay

The QuantiVirus™ SARS-CoV-2 Multiplex Test is designed as a real-time RT-qPCR assay targeting three distinct regions of the viral genome: the Orf1ab, N, and E genes. This redundancy is critical for maintaining diagnostic accuracy even as the virus undergoes mutations. Additionally, the assay includes a human RNase P internal control to verify sample integrity and the success of the nucleic acid extraction process.

High-Throughput Automation and Platform Compatibility

To address the need for large-scale testing, the assay was integrated with the MGI MGISP-960 automated workstation, which can process 192 samples in approximately 80 minutes. Validation was conducted across four major qPCR platforms to ensure broad laboratory utility:

  • Applied Biosystems 7500 Fast Dx
  • Bio-Rad CFX384
  • Roche LightCycler 480 II
  • Thermo Fisher QuantStudio 5

Clinical and Community Samples

The study utilized a diverse range of samples for validation:

  1. Reference Materials: SeraCare Accuplex SARS-CoV-2 reference panels were used to determine the Limit of Detection (LOD).
  2. Clinical NPS Samples: 85 known positive and 90 known negative samples (previously characterized by the Abbott m2000 system).
  3. Paired Specimens: 20 sets of matched NPS and saliva samples from recovering COVID-19 patients.
  4. Community Screening: 389 saliva samples collected from asymptomatic individuals in California.

Key Insights and Results

Overcoming Saliva Viscosity

A significant technical hurdle in saliva testing is the specimen's viscosity, which can interfere with automated pipetting. The researchers addressed this by using a collection kit containing Viral Transport Media (VTM) to dilute the saliva by 50% immediately upon collection. This step stabilized the viral RNA and ensured the sample was compatible with high-throughput liquid handling systems.

Analytical Sensitivity and Specificity

The LOD for the QuantiVirus™ test was confirmed at 100–200 copies/mL, indicating high sensitivity. In clinical evaluations using NPS samples, the test achieved a Positive Percentage Agreement (PPA) of 100% and a Negative Percentage Agreement (NPA) of 98.9%. Cross-reactivity testing against a panel of common respiratory pathogens (including MERS-CoV and various Influenza strains) showed no false positives, confirming high specificity.

Saliva vs. NPS Performance

In the comparison of 20 paired samples, the QuantiVirus™ test showed an 80% concordance rate between saliva and NPS. Notably, the QuantiVirus™ assay detected the virus in three patients that the Abbott m2000 assay missed, suggesting that the lower LOD of the QuantiVirus™ test provides a sensitivity advantage in patients with low viral loads.

Feasibility of Sample Pooling

Pooling samples is a vital strategy for conserving reagents and increasing throughput during periods of high demand. The study evaluated 1:6 and 1:12 pooling ratios:

  • 6-Sample Pooling: Maintained a sensitivity of 94.8% and a specificity of 100%.
  • 12-Sample Pooling: Resulted in a drop in the Negative Predictive Value (NPV) to 80%.

These results suggest that a 6-sample pooling strategy is a highly effective "sweet spot" for maintaining diagnostic integrity while significantly expanding testing capacity.

Discussion and Conclusion

The findings demonstrate that saliva is a reliable and effective specimen for SARS-CoV-2 detection. The QuantiVirus™ multiplex test provides the sensitivity required to detect low viral titers, which is essential for identifying asymptomatic carriers in community screening. While the study noted an 80% concordance between saliva and NPS in recovering patients, the differences likely stem from the biological distribution of the virus at different stages of infection rather than assay failure.

In conclusion, the QuantiVirus™ SARS-CoV-2 multiplex test, combined with saliva collection and automated processing, offers a patient-friendly, high-throughput, and sensitive solution for large-scale COVID-19 surveillance. The feasibility of 6-sample pooling further enhances its utility for monitoring populations and managing the ongoing public health challenge.

Summary updated

Abstract

Abstract Background Sensitive and high throughput molecular detection assays are essential during the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vast majority of the SARS-CoV-2 molecular assays use nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens collected from suspected individuals. However, using NPS or OPS as specimens has apparent drawbacks, e.g. the collection procedures for NPS or OPS specimens can be uncomfortable to some people and may cause sneezing and coughing which in turn generate droplets and/or aerosol particles that are of risk to healthcare workers, requiring heavy use of personal protective equipment. There have been recent studies indicating that self-collected saliva specimens can be used for molecular detection of SARS-CoV-2 and provides more comfort and ease of use for the patient. Here we report the performance of QuantiVirus™ SARS-CoV-2 multiplex test using saliva as the testing specimens with or without pooling. Methods Development and validation studies were conducted following FDA-EUA and molecular assay validation guidelines. Using SeraCare Accuplex SARS-CoV-2 reference panel, the limit of detection (LOD) and clinical evaluation studies were performed with the QuantiVirus™ SARS-CoV-2 multiplex test. For clinical evaluation, 85 known positive and 90 known negative clinical NPS samples were tested. Additionally, twenty paired NPS and saliva samples collected from recovering COVID-19 patients were tested and the results were further compared to that of the Abbott m2000 SARS-CoV-2 PCR assay. Results of community collected 389 saliva samples for COVID-19 screening by QuantiVirus™ SARS-CoV-2 multiplex test were also obtained and analyzed. Moreover, saliva pooling with 6 and 12 samples together were also evaluated. Results The LOD for the QuantiVirus™ SARS-CoV-2 multiplex test was confirmed to be 100-200 copies/mL. The clinical evaluation using contrived saliva samples indicated that the positive percentage agreement (PPA) of the QuantiVirus™ SARS-CoV-2 multiplex test is 100% at 1xLOD, 1.5xLOD and 2.5xLOD. No cross-reactivity was observed for the QuantiVirus™ SARS-CoV-2 multiplex test with common respiratory pathogens. Testing of clinical samples showed a positive percentage agreement (PPA) of 100% (95% CI: 94.6% to 100%) and a negative percentage agreement (NPA) of 98.9% (95% CI: 93.1% to 99.9%). QuantiVirus ™SARS CoV-2 multiplex test had 80% concordance rate and no significant difference ( p =0.13) in paired saliva and NPS specimens by Wilcoxon matched pairs signed rank test. Positive test rate was 1.79% for 389 saliva specimens collected from the communities for COVID-19 screening. Preliminary data showed that saliva sample pooling up to 6 samples for SARS-CoV-2 detection is feasible (sensitivity 94.8% and specificity 100%). Conclusion The studies demonstrated that the QuantiVirus™ SARS-CoV-2 multiplex test has a LOD of 200 copies/mL in contrived saliva samples. The clinical performance of saliva-based testing is comparable to that of NPS-based testing. Pooling of saliva specimens for SARS-CoV-2 detection is feasible. Saliva based and high-throughput QuantiVirus™SARS-CoV-2 multiplex test offers a highly desirable test during the ongoing COVID-19 pandemic.
BibTeX
@misc{sun2020saliva,
  author = {Qing Sun and Jonathan Li and Hui Ren and Larry Pastor and Yulia Loginova and Roberta Madej and Kristopher Taylor and Joseph K. Wong and Zhao Zhang and Aiguo Zhang and Chuanyi M. Lu and Michael Y. Sha},
  title = {{Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test}},
  year = {2020},
  doi = {10.1101/2020.10.27.20219196},
  howpublished = {medRxiv},
}
Figure